Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.
News|Videos|February 27, 2017
Dr Yehuda Handelsman Discusses New Alternatives to Basal Insulin
Recent advances in insulin formulations and innovative drug classes have made it easier than ever to manage diabetic patients’ glucose levels, according to Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America.
Advertisement
Recent advances in insulin formulations and innovative drug classes have made it easier than ever to manage diabetic patients’ glucose levels, according to Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America.
Advertisement
Related to this article
In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.
Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
Advertisement
Advertisement
Trending on AJMC
1
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
2
Occasional Cannabis Use Linked to 40% Higher Odds of Stroke
3
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
4
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
5